Lv1
60 积分 2024-05-27 加入
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
17天前
已完结
LRRK2 activation in idiopathic Parkinson’s disease
1个月前
已完结
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
1个月前
已完结
临床诊疗与药物应用新进展
1个月前
已关闭
Spinocerebellar ataxia type 3: from pathogenesis to promising therapeutics
3个月前
已完结
Discovery and development of bispecific antibodies
3个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
3个月前
已完结
The present and future of bispecific antibodies for cancer therapy
3个月前
已完结
Parkinson disease therapy: current strategies and future research priorities
3个月前
已完结
Hexachlorocyclohexane Dusts and Fogs to Control Grasshoppers1
3个月前
已完结
皖公网安备34019202002308
